We report results of imaging of the vaccination response for patients who received a novel PET tracer targeted at PD-L1 (Wichmann et al. 2023) during a cancer imaging trial (Hegi-Johnson et al. 2022a, b), conducted during the COVID-19 pandemic. The gene discussed is CD274; the disease is cancer.